Open AccessThe Potential Role of Soluble Angiotensin Converting Enzyme 2 As A Left Ventricular Dysfunction Biomarker
Author(s) -
Sidhi Laksono,
Budhi Setianto,
Ananta Siddhi Prawara
Publication year - 2021
Publication title -
journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.121
H-Index - 5
eISSN - 2075-5384
pISSN - 1997-9797
DOI - 10.3329/jom.v22i2.56702
Subject(s) - medicine , biomarker , heart failure , angiotensin converting enzyme 2 , cardiology , natriuretic peptide , diastole , metalloproteinase , brain natriuretic peptide , angiotensin ii , matrix metalloproteinase , blood pressure , disease , covid-19 , biochemistry , biology , infectious disease (medical specialty)
Left ventricular (LV) dysfunction is a part of the common pathophysiologic mechanism for the development of heart failure (HF). LV dysfunction can be classified into left ventricular systolic dysfunction (LVSD) and left ventricular diastolic dysfunction (LVDD). Currently, B-type Natriuretic Peptide (BNP) and N-Terminal Pro-BNP (NT-proBNP) are the most common marker used to determine HF. Both of them are used as diagnostic and prognostic marker. Angiotensin Converting Enzyme 2 (ACE2) was found as an ACE homolog, located in the cell membrane of the heart. ACE2 has a cardioprotective role in turning AngII to Ang1-7. ACE2 can be cleaved by A Disintegrin and Metalloproteinase 17 (ADAM17)/TNF-a converting enzyme (TACE) so that it can be detected in the plasma as soluble ACE2. Soluble ACE2 possessed a potential role as LV dysfunction diagnostic or prognostic biomarker.J MEDICINE 2021; 22: 127-131